Treatment of Colon Cancer by Degradable rrPPC Nano-Conjugates Delivered STAT3 siRNA (2020)
Sequence: cRGD motif + R9 (RRRRRRRRR)
| Experiment Id | EXP002022 |
|---|---|
| Paper | Treatment of Colon Cancer by Degradable rrPPC Nano-Conjugates Delivered STAT3 siRNA |
| Peptide | cRGD-R9 |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | rrPPC 50 µg/mouse (siRNA:rrPPC = 1:10 w/w) |
| Rna Concentration | siRNA 5 µg/mouse |
| Mixing Ratio | siRNA:rrPPC = 1:10 (w/w) |
| Formulation Format | polymeric nanoparticle (rrPPC/siRNA) |
| Formulation Components | PEI1.8K + PEG + cholesterol + cRGD-R9 peptide |
| Size Nm | 195.00 |
| Zeta Mv | 41.90 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c mice (C26 colon cancer: abdominal, subcutaneous, lung metastasis models) |
| Administration Route | intraperitoneal, intratumoral, intravenous |
| Output Type | tumor growth suppression / apoptosis / anti-metastasis |
| Output Value | Significant tumor weight reduction; fewer nodules; suppressed metastasis |
| Output Units | |
| Output Notes | STAT3 siRNA delivery led to apoptosis (TUNEL), reduced angiogenesis (CD31), and tumor regression |
| Toxicity Notes | No major organ toxicity; normal blood biochemistry |
| Curation Notes |